- Home
- OSBC vs ABUS Comparison
OSBC vs ABUS Comparison
Compare OSBC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSBC | ABUS |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 888.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OSBC | ABUS |
|---|---|---|
| Price | $20.46 | $4.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $22.63 | $5.00 |
| AVG Volume (30 Days) | 407.0K | ★ 2.0M |
| Earning Date | 01-21-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $311,343,000.00 | $14,606,000.00 |
| Revenue This Year | $25.32 | $125.30 |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $12.75 | ★ N/A |
| Revenue Growth | 14.55 | ★ 116.64 |
| 52 Week Low | $14.14 | $2.71 |
| 52 Week High | $22.00 | $5.10 |
Technical Indicators
Market Signals| Indicator | OSBC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 47.48 |
| Support Level | $20.45 | $3.62 |
| Resistance Level | $21.33 | $4.26 |
| Average True Range (ATR) | 0.63 | 0.29 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 54.95 | 58.18 |
Price Performance
Historical ComparisonAbout OSBC Old Second Bancorp Inc.
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The Company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.